

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
February 13, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Salix Pharmaceuticals, Ltd.**

**File No. 000-23265 - CF#29017**

---

Salix Pharmaceuticals, Ltd. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 8, 2012.

Based on representations by Salix Pharmaceuticals, Ltd. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.95	through November 8, 2022
Exhibit 10.96	through November 8, 2022
Exhibit 10.97	through November 8, 2022
Exhibit 10.98	through November 8, 2022
Exhibit 10.99	through November 8, 2022
Exhibit 10.100	through November 8, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Kathleen Krebs  
Special Counsel